Metastatic Melanoma Cancer Diagnostic Market is Set to Globally Reach US$ 7,601.0 Million by 2034 at 7.70% CAGR | Fact.MR

The metastatic melanoma cancer diagnostic market is projected to be worth US$ 3,632.6 million in 2024. Growth is projected to be robust with a CAGR of 7.70% during the period 2024-2034. Expected growth is expected to drive the market to a whopping size of US$ 7,601.0 million by 2034.

Improvements in early detection technology help boost the rate of diagnoses, driving market growth. Over the last several years, there has been an increase in metastatic melanoma cancer cases in the overall population. This has tremendously increased the demand for successful treatments and processes that reduce the effects of metastatic melanoma.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9551

What are the Factors That Pose Challenges to the Growth of the Metastatic Melanoma Cancer Diagnostic Market?

"Limited Awareness and Education, Cost of Advanced Diagnostics, and Global Economic Factors to Slow down Market Growth"

Limited education and awareness among the common population regarding the advantages of metastatic melanoma cancer diagnostic therapies is retarding the growth of the market. Even with active promotion by the government along with private healthcare units, there still exists a wide knowledge gap in the common populace regarding this, which is badly affecting the market growth.

This element keeps the market away from a large number of cost-conscious buyers, particularly from underdeveloped and developing regions of the world. Apart from this, international economic conditions, including recessionary economies and economic uncertainties, retard metastatic melanoma cancer diagnostic treatment market growth.

Country-wise Insights

The North American metastatic melanoma cancer diagnosis market is also ready for unprecedented growth, anticipating a robust CAGR of 8.40% until 2034. The boom is largely driven by the growing demand for metastatic melanoma cancer diagnoses in leading countries, especially the United States and Mexico. As of 2024, the United States leads the metastatic melanoma cancer diagnosis industry with an estimated 83.10% market share.

The United States metastatic melanoma cancer diagnostic market was valued at US$ 1,728 million in 2024, holding a revenue share of 47.6%, and is also set to grow further at a CAGR of 8.40% from 2024 to 2034. The United States metastatic melanoma cancer diagnostic market is forecasted to be valued at US$ 1,436 million in 2024. United States demand for metastatic melanoma cancer diagnostic is forecasted to grow at a CAGR of 8.7% during the period from 2024 to 2034.

The metastatic melanoma cancer diagnostic market in China has been estimated at US$ 60 million for the year 2024, capturing a value of 76.2% for the East Asian market. The metastatic melanoma cancer diagnostic sales are expected to achieve a CAGR of 10.4% until 2034.

Category-wise Insights

Depending on the test type, the biopsy section is projected to own a market share of 27.0% in the year 2024. At the same time, the segment of PET scanning is expected to account for 32.0%, making important contributions to resource diversification and market stability. Depending on the end users, the pathology labs section claims supremacy among metastatic melanoma cancer diagnosis markets in the year 2024 at 51.80%.

Competitive Landscape

Global metastatic melanoma cancer diagnostics market includes a large number of firms, like Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Abbott Laboratories, Qiagen, etc.

These large corporate players possess an established position within the world's metastatic melanoma cancer diagnosis treatment market, thanks to the long existence of these businesses. They also dedicate resources toward exploring and researching highly advanced diagnosis techniques. The little companies have no choice but to depend on such firms in their efforts to instill technology upgrade features within equipment.

Recent Development

In February 2023, Avero Diagnostics launched successfully AMBLor, a first-in-class laboratory test for low-risk early-stage melanoma identification. The technology was licensed in September 2022 from AMLo Biosciences.
DeepX Diagnostics was given FDA 510(k) clearance for its digital dermatoscope, DermoSight, in June 2023. With over 180,000 tests having been completed in Europe, it is going to enter the U.S. market.
In February 2023, Dermalyser showed promise with a 95% sensitivity and 86% specificity in primary care practice, presenting an AI-based potential solution for the identification of malignant melanomas and to lighten the work burden on dermatologists.

Browse Full Report: https://www.factmr.com/report/metastatic-melanoma-cancer-diagnostic-market

Metastatic Melanoma Cancer Diagnostic Market - Segmentation

By Test:
Biopsy
Local excision/excisional biopsy
Punch biopsy
Shave biopsy
Fine needle aspiration (FNA) biopsy
Sentinel lymph node biopsy
Chest X-ray
Ultrasound
CT Scan
MRI
PET SCAN
By Service Provider:
Hospitals
Pathology Laboratories
Cancer Research Centres
By Region:
North America
Latin America
Europe
Asia Pacific
The Middle East & Africa (MEA)

Check out More Related Studies Published by Fact.MR:

Cardiac Ablation Technologies Market
https://www.factmr.com/report/4426/cardiac-ablation-technologies-market

Imaging Agents Market
https://www.factmr.com/report/imaging-agents-market

Clinical Trial Imaging Market
https://www.factmr.com/report/clinical-trial-imaging-market

Movement Disorder Market
https://www.factmr.com/report/329/movement-disorder-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.